Dezecapavir vs Islatravir/lenacapavir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Dezecapavir
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.
Next expected readout: February 2027 · NCT07934719 (registry estimate)
Reported efficacy
Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) (unclear)
Result source: NCT06039579
Islatravir/lenacapavir
Developed by Gilead Sciences and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dezecapavir | Islatravir/lenacapavir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Trial running · NCT06630286 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Trial running · NCT06630286 |
| CD4 count, change (week 48) | —Not reported | —Trial running · NCT06630286 |
HIV-1 RNA below 50 copies/mL (week 48)
- Dezecapavir
- —Not reported
- Islatravir/lenacapavir
- —Trial running · NCT06630286
HIV-1 RNA 50 copies/mL or more (week 48)
- Dezecapavir
- —Not reported
- Islatravir/lenacapavir
- —Trial running · NCT06630286
CD4 count, change (week 48)
- Dezecapavir
- —Not reported
- Islatravir/lenacapavir
- —Trial running · NCT06630286
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Islatravir/lenacapavir: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dezecapavir: 3 of 4 rows · Islatravir/lenacapavir: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dezecapavir |
|---|---|
| Dropout rate | 0%Dose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%1875 mg PiB NCT05393271 · Phase 1 · monotherapy 0%625 mg PiB NCT05393271 · Phase 1 · monotherapy 0%400 mg PiB NCT05393271 · Phase 1 · monotherapy 0%300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg Tablet NCT05393271 · Phase 1 · monotherapy 0%125 mg PiB NCT05393271 · Phase 1 · monotherapy 0%25 mg PiB NCT05393271 · Phase 1 · monotherapy |
| Discontinued due to AEs | —Dose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —1875 mg PiB NCT05393271 · Phase 1 · monotherapy —625 mg PiB NCT05393271 · Phase 1 · monotherapy —400 mg PiB NCT05393271 · Phase 1 · monotherapy —300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination —200 mg PiB NCT05393271 · Phase 1 · monotherapy —200 mg PiB NCT05393271 · Phase 1 · monotherapy —200 mg Tablet NCT05393271 · Phase 1 · monotherapy —125 mg PiB NCT05393271 · Phase 1 · monotherapy —25 mg PiB NCT05393271 · Phase 1 · monotherapy |
| Serious AEs | —Dose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results0%Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%1875 mg PiB NCT05393271 · Phase 1 · monotherapy 0%625 mg PiB NCT05393271 · Phase 1 · monotherapy 0%400 mg PiB NCT05393271 · Phase 1 · monotherapy 0%300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg Tablet NCT05393271 · Phase 1 · monotherapy 0%125 mg PiB NCT05393271 · Phase 1 · monotherapy 0%25 mg PiB NCT05393271 · Phase 1 · monotherapy |
| Most frequent reported AEs | Dose Level 1a influenza 14.3% (placebo 33.3%) proteinuria 14.3% (placebo 0%) rash 14.3% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 show 14 more resultsDose Level 1 headache 14.3% (placebo 0%) upper respiratory tract infection 14.3% (placebo 0%) alanine aminotransferase increased 0% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Dose Level 2 arthralgia 16.7% (placebo 0%) dermatophytosis 16.7% (placebo 0%) ear pain 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Dose Level 2 asthenia 16.7% (placebo 0%) dermatitis acneiform 16.7% (placebo 0%) diarrhoea 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Pre-specified Dose nausea 28.6% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) aspartate aminotransferase increased 14.3% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose vessel puncture site haematoma 28.6% (placebo 0%) headache 14.3% (placebo 0%) hypokalaemia 14.3% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 1875 mg PiB total bile acids increased 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 625 mg PiB gastroenteritis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 400 mg PiB dry skin 16.7% (placebo 0%) skin abrasion 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 300 mg + Midazolam (MDZ) PiB somnolence 25% (placebo 0%) dizziness 12.5% (placebo 0%) feeling abnormal 12.5% (placebo 0%) NCT05393271 · Phase 1 · combination 200 mg PiB activated partial thromboplastin time prolonged 33.3% (placebo 0%) blood triglycerides increased 16.7% (placebo 0%) lipase increased 16.7% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 200 mg PiB diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 0%) nausea 33.3% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 200 mg Tablet medical device site dermatitis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 125 mg PiB medical device site dermatitis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 25 mg PiB blood creatine phosphokinase increased 16.7% (placebo 20%) haematocrit decreased 16.7% (placebo 0%) haemoglobin decreased 16.7% (placebo 0%) NCT05393271 · Phase 1 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 9 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dezecapavir
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dezecapavir's landscape · Islatravir/lenacapavir's landscape